Peer review refers to the work done during the screening of submitted manuscripts and funding applications. This process encourages authors to meet the accepted standards of their discipline and reduces the dissemination of irrelevant findings, unwarranted claims, unacceptable interpretations, and personal views. Publications that have not undergone peer review are likely to be regarded with suspicion by academic scholars and professionals.
Bone Marrow Transplantation (BMT) is a useful strategy for the treatment of leukemia, severe combined immune deficiency, enzyme deficiencies, autoimmune disease, and osteoporosis. Furthermore, Bone Marrow Transplantation plays an important role in the induction of immune tolerance in organ transplantation. Bone marrow is a spongy tissue, and is made up of Hematopietic Stem Cells (HSCs), Mesenchymal Stem Cells (MSCs), and various blood cells. HSCs differentiate into common myeloid- and lymphoid-precursor cells and then terminally differentiate into erythrocytes, monocytes, platelets, neutrophils, dendritic cells and other cells. MSCs can differentiate into not only mesoderm derived-cells such as adipocytes, osteoblasts, and osteoclasts, but also endodermand ectoderm-derived cells. Intra-Bone Marrow-BMT (IBM-BMT) has been proven to be the best strategy for allogeneic BMT as it results in the rapid recovery of hemopoietic function and the restoration of T cell functions since it can replace not only HSCs but also MSCs. It has been reported that IBM-BMT plays an important role in therapies for various diseases in animal models such as those of rheumatoid arthritis, Alzheimerâs disease and diabetes. Moreover, Intra-Bone Marrow-BMT has induced persistent donor-specific tolerance, and enables the use of reduced radiation doses as conditioning regimens in organ transplantation. Allogeneic Bone Marrow Transplantation is an effective immunotherapy for childhood leukemia. (Susumu Ikehara, Advances in Leukemia Treatment with Bone Marrow Transplantation)
Last date updated on June, 2021